The developer says it is harnessing parvovirus vectors that can deliver larger gene therapy payloads with enhanced tissue specificity and with minimal neutralizing immunity.
Vertex is set to acquire Semma, which is developing a stem cell curative treatment for type 1 diabetes and expects the deal to ‘rapidly advance’ its potential therapy.